Archive | September, 2011

Michael J. Fox Op-Ed runs in Birmingham and Rochester

Birmingham News and Rochester's Democrat and Chronicle have recently published an op-ed by Michael J. Fox that focuses on the critical role clinical trial volunteers play in advancing Parkinson's research.

Continue reading...

Paracelsus-Elena Klinik featured in Hessische Allgemeine

The Paracelsus-Elena Klinik in Kassel, German, is featured in the Hessische Allgemaine. This article was originally published in German, and has been translated into English.

Continue reading...

Statistics about data downloads and specimen requests on PPMI-info.org

A new page has been added to the website to show the number of data downloads and specimen requests, as well as where people who download the data are from globally and by sector.

Continue reading...

Qualification study in healthy volunteers prompts investigators to explore fluctuation of markers in PD subjects

PPMI study leadership is repeating a qualification study in controls that was completed last fall with a group of PD subjects and older controls to detect changes in biomarkers over the course of a day.

Continue reading...

PPMI Recruitment Update: Study reaches 200 subjects enrolled

Fall kicks off to a great start as PPMI passes the 200th subject mark, one third of the way to meeting the study's recruitment goal.

Continue reading...

PPMI study commissions first interlaboratory study of alpha-synuclein immunoassay performance

The Bioanalytics core of PPMI recently organized the first interlaboratory study to assess the within-center precision of immunoassays for a-SYN measurement in CSF. The long term goal of these studies to optimize and validate an a-SYN biomarker assay for use in the PPMI and other research biomarker studies of PD and PDD as well as to set the stage for wider clinical use of these diagnostic assays beyond specialized research centers. The initial results of these detailed statistical analyses were discussed amongst the participants and will be discussed at the MJFF-hosted PD Therapeutics meeting.

Continue reading...